Human Integrin alpha4 beta7/LPAM-1 (Research Grade Vedolizumab Biosimilar) PE-conjugated Antibody
R&D Systems, part of Bio-Techne | Catalog # FAB10078P
Recombinant Monoclonal Antibody For Research Use Only
Conjugate
Catalog #
Key Product Details
Species Reactivity
Human
Applications
Flow Cytometry
Label
Phycoerythrin (Excitation = 488 nm, Emission = 565-605 nm)
Antibody Source
Recombinant Monoclonal Human IgG1 Clone # Hu117
Product Specifications
Immunogen
Human Integrin alpha4 beta7/LPAM‑1
Specificity
Detects human Integrin alpha4 beta7/LPAM‑1 in direct ELISAs. This non-therapeutic antibody uses the same variable region sequence as the therapeutic antibody Vedolizumab. This product is for research use only.
Clonality
Monoclonal
Host
Human
Isotype
IgG1
Scientific Data Images
Detection of Integrin alpha 4 beta 7/LPAM-1 in Human PBMC by Flow Cytometry.
Human PBMC were stained with (A) Human Anti-Human Integrin alpha 4 beta 7/LPAM-1 (Research Grade Vedolizumab Biosimilar) PE-conjugated Monoclonal Antibody (Catalog # FAB10078P) or (B) no primary antibody, followed by Mouse anti-Human CD3 APC-conjugated Monoclonal Antibody (Catalog # FAB100A). View our protocol for Staining Membrane-associated Proteins.Applications
Application
Recommended Usage
Flow Cytometry
10 µL/106 cells
Sample: Human PBMC
Sample: Human PBMC
Please Note: Optimal dilutions of this antibody should be experimentally determined.
Formulation, Preparation, and Storage
Purification
Protein A or G purified from cell culture supernatant
Formulation
Supplied in a saline solution containing BSA and Sodium Azide.
Shipping
The product is shipped with polar packs. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage
Protect from light. Do not freeze.
- 12 months from date of receipt, 2 to 8 °C as supplied.
Background: Integrin alpha 4 beta 7/LPAM-1
Alternate Names
CD49d/beta7, LPAM-1, LPAM1
Gene Symbol
ITGA4
Additional Integrin alpha 4 beta 7/LPAM-1 Products
Product Specific Notices
For research use only
Loading...
Loading...
Loading...
Loading...
Loading...
Loading...